Inhaled Technosphere Insulin

Phase 3Small molecule

Inhaled Technosphere Insulin is one of 19 small molecule programs targeting Gestational Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gestational DiabetesRecruiting

Gestational DiabetesPhase 3

Recruiting

Competition

Competitive Landscape

24 competitors in Gestational Diabetes

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

29 2

Diabeta

Pfizer

Approved

9 3

Victoza

Novo Nordisk

Approved

1 4

Actigall

Calciferol

Byetta

2 7

Ozempic

Novo Nordisk

Phase 3

1 8

Insulin 320

Novo Nordisk

Phase 3

6 9

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 10

Miochol

BBausch Health Americas, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gestational Diabetes1 trial

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Recruiting·JJaeb Center for Health Research·Phase 2/3·NCT06535789·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled Technosphere Insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled Technosphere Insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled Technosphere Insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jaeb Center for Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJaeb Center for Health Research

Inhaled Technosphere Insulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gestational Diabetes1 trial

References

Drug Info

Quick Facts

Related News